Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Using ketamine to treat severe acute brain injuries

Official title: S-ketamine for Cortical Spreading Depolarisation in Patients With Severe Acute Brain Injury

Run by Copenhagen University Hospital, Rigshospitalet · NCT05095857 · Data updated 2026-11-12

This study is testing if S-ketamine can help people with severe brain injuries feel better and improve their recovery compared to a placebo.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment400 (estimated)
SponsorCopenhagen University Hospital, Rigshospitalet
Academic / other
Locations1 site (Copenhagen)
StatusRecruiting
StartedSeptember 15, 2023
Main results expectedSeptember 15, 2028
Study endsSeptember 15, 2028
Registry record updatedJune 26, 2024
Trial IDNCT05095857 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older who have been admitted to the neuro-intensive care unit with specific types of severe acute brain injuries and are planned for surgery.

Probably not a fit

Patients who are not undergoing surgery or have conditions such as known allergies to S-ketamine or active anti-psychotic treatment may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the efficacy and safety of S-ketamine in patients suffering from severe acute brain injuries, such as traumatic brain injury and hemorrhages. It focuses on the role of cortical spreading depolarisations, which are linked to poor outcomes in these patients. Participants will be randomly assigned to receive either S-ketamine or a placebo while being monitored in a neuro-intensive care unit. The study aims to assess the feasibility of this treatment approach and its potential to improve neurological outcomes.

Why it matters

Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients with severe acute brain injuries.

How similar studies have gone: While the use of ketamine in this context is novel, preliminary evidence suggests it may inhibit harmful brain activity, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years.
* Admitted to the NICU with a diagnosis of traumatic brain injury (TBI), aneurysmal subarachnoid haemorrhage (aSAH) or spontaneous intracerebral haemorrhage (ICH).
* Planned for surgery with a supratentorial craniotomy or craniectomy.
* Expected to continue sedation and mechanical ventilation after surgery.

Exclusion Criteria:

* Neither patient or next of kin understand Danish or English.
* Known allergy to S-ketamine (the active pharmaceutical ingredient or the excipients).
* Wake-up call to occur immediately after surgery.
* Pregnancy (all female participants aged ≤ 50 years will have a urine or blood hCG taken to control for pregnancy).
* Active anti-psychotic treatment before admission.
* Current abuse of ketamine.
* Decision to withdraw active treatment.
* ICH secondary to a known brain tumour at the time of inclusion.

Since this is an emergency trial informed consent will be obtained from a trial guardian before inclusion of the participant, and informed consent will be sought from next of kin as soon as possible.

Where it's running

  • Rigshospitalet
    Copenhagen, Denmark
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.